Inventor
XU JEAN
US50 patents
⚠️ This page may combine multiple inventors who share the name “XU JEAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
CELGENE CORP
14 patentsUS7893101B2Feb 22, 2011
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CELGENE CORP44 citations98
US9018243B2Apr 28, 2015
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CELGENE CORP13 citations93
US9221788B2Dec 29, 2015
Salts and solid forms of (S)-3-(4- (4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
CELGENE CORP21 citations92
US9751853B2Sep 5, 2017
Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CELGENE CORP4 citations84
US9629849B2Apr 25, 2017
Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
CELGENE CORP7 citations84
US10463672B2Nov 5, 2019
Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
CELGENE CORP2 citations73
US9884062B2Feb 6, 2018
Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
CELGENE CORP2 citations73
US9433606B2Sep 6, 2016
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CELGENE CORP3 citations73
US9969713B2May 15, 2018
Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CELGENE CORP1 citations63
US9249121B2Feb 2, 2016
Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
CELGENE CORP2 citations63
US12343346B2Jul 1, 2025
Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
CELGENE CORP0 citations62
US11241439B2Feb 8, 2022
Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
CELGENE CORP0 citations62
US10596180B2Mar 24, 2020
Salts and solid forms of (S)-3-(4-((4-(morpholinomethyl)benzyl) oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
CELGENE CORP0 citations52
US9085551B2Jul 21, 2015
Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione
CELGENE CORP1 citations51
JANSSEN BIOTECH INC
9 patentsUS10704025B2Jul 7, 2020
Use of noggin, an ALK5 inhibitor and a protein kinase c activator to produce endocrine cells
JANSSEN BIOTECH INC2 citations73
US10471104B2Nov 12, 2019
Lowering blood glucose
JANSSEN BIOTECH INC1 citations73
US10456424B2Oct 29, 2019
Pancreatic endocrine cells and methods thereof
JANSSEN BIOTECH INC3 citations73
US11708562B2Jul 25, 2023
Differentiation of human embryonic stem cells
JANSSEN BIOTECH INC0 citations63
US12558378B2Feb 24, 2026
Methods for lowering blood glucose
JANSSEN BIOTECH INC0 citations62
US12441985B2Oct 14, 2025
Methods for making insulin in vivo
JANSSEN BIOTECH INC0 citations62
US11890304B2Feb 6, 2024
Pancreatic endocrine cells and methods thereof
JANSSEN BIOTECH INC0 citations62
US11369642B2Jun 28, 2022
Methods for lowering blood glucose
JANSSEN BIOTECH INC0 citations62
US9593310B2Mar 14, 2017
Differentiation of human embryonic stem cells
JANSSEN BIOTECH INC0 citations52
SIGNAL PHARM LLC
7 patentsUS9814713B2Nov 14, 2017
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC14 citations92
US9365524B2Jun 14, 2016
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
SIGNAL PHARM LLC22 citations92
US9403829B2Aug 2, 2016
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use
SIGNAL PHARM LLC13 citations81
US9359364B2Jun 7, 2016
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one
SIGNAL PHARM LLC10 citations81
US10047090B2Aug 14, 2018
Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
SIGNAL PHARM LLC3 citations68
US9827243B2Nov 28, 2017
Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one
SIGNAL PHARM LLC0 citations51
US10513519B2Dec 24, 2019
Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use
SIGNAL PHARM LLC0 citations47
XU JEAN
6 patentsUS9096832B2Aug 4, 2015
Differentiation of human embryonic stem cells
XU JEAN40 citations97
US8785185B2Jul 22, 2014
Differentiation of human embryonic stem cells
XU JEAN32 citations93
US8785184B2Jul 22, 2014
Differentiation of human embryonic stem cells
XU JEAN31 citations92
US9150833B2Oct 6, 2015
Differentiation of human embryonic stem cells
XU JEAN5 citations84
US10076544B2Sep 18, 2018
Differentiation of human embryonic stem cells
XU JEAN3 citations73
US9752125B2Sep 5, 2017
Differentiation of human embryonic stem cells
XU JEAN0 citations52
CELGENE CAR LLC
4 patentsUS10882867B2Jan 5, 2021
Forms and compositions of a MK2 inhibitor
CELGENE CAR LLC8 citations82
US11629153B2Apr 18, 2023
Forms and compositions of a MK2 inhibitor
CELGENE CAR LLC1 citations60
US10005760B2Jun 26, 2018
Forms and compositions of an ERK inhibitor
CELGENE CAR LLC1 citations60
US10202364B2Feb 12, 2019
Forms and compositions of an ERK inhibitor
CELGENE CAR LLC0 citations49
JANSSEN PHARMACEUTICA NV
3 patentsLIFESCAN INC
2 patentsMULLER GEORGE W
2 patentsUS8629173B2Jan 14, 2014
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
MULLER GEORGE W11 citations92
US8093283B2Jan 10, 2012
Solid forms comprising (+)-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisinoline-1,3-dione, compositions thereof, and uses thereof
MULLER GEORGE W17 citations92